AZD1152
Drug1200 mg, iv, 7 day infusion
NCT Number: NCT00952588
The purpose of this study is to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients.
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Phase 2 / Phase 3
Research Site, Westmead, New South Wales, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1200 mg, iv, 7 day infusion
20 mg, sc, bd, 10 days
Time frame: IWG Cheson criteria every 28 days from randomization for study duration (24 months, between 2009 - 2011)
Percentage of patients achieving either a complete response (CR) or a confirmed complete remission with incomplete recovery of neutrophils or platelets (confirmed CRi). Per Cheson Criteria: Confirmed complete remission (CRi) is defined as a disappearance of blasts in the peripheral blood; a decrease in bone marrow blasts to <5% total bone marrow nucleated cells demonstrated in bone marrow aspirate; absence of Auer rods; no persistent extramedullary leukaemia. Complete response (CR) is defined as all requirements to meet CRi and in addition: recovery of neutrophils to ≥1.0 x 109/L and platelets to ≥100 x 109/L; transfusion-independence.
Time frame: DoR was measured every 28 days from randomization for study duration (24 months, between 2009 - 2011)
DoR was defined for the median of days which showed a confirmed CRi or CR, as the time from first documented evidence of CRi or CR until the first documented sign of disease progression or death. Duration of Response was measured from the Response Start date until evidence of patient relapse or death. Stage I : 45 patients randomized in a 2:1 ratio to AZD1152 or LDAC. Transition phase: enrollment of up to 30 additional patients randomized as per stage I.
Time frame: DFS was measured every 28 days from randomization for study duration (24 months, between 2009 - 2011)
Disease-free Survival is defined as the time from randomisation to relapse or death from any cause.
Time frame: Response was measured every 28 days from randomization for study duration (24 months, between 2009 - 2011)
TTCR is measured as time from randomization to either a complete response (CR) or a confirmed complete remission with incomplete recovery of neutrophils or platelets (confirmed CRi)
Time frame: Assessed from randomisation until the date of death from any cause, assessed up to 24 months
Overall Survival is defined as the median time from randomisation to death from any cause. Patients who were not known to have died at the time of the analysis were censored at the date they were last known to be alive.
Time frame: TOI was measured every 28 days from randomization for study duration (24 months, between 2009 - 2011)
TOI is derived from the sum of the Functional Well Being (FWB), Physical Well Being (PWB) and additional subscales of the FACT-Leu. The TOI subscale consists of 31 items with TOI scores ranging from 0 to 124. The TOI is described as a summary measure of HRQoL. Higher scores indicate better HRQoL. Negative changes from baseline indicate a worsening of HRQoL while positive changes indicate an improvement in HRQoL. A response of "Worsened" was a change from baseline in score of less than or equal to -9.
Time frame: FACT-Leu was measured every 28 days from randomization for study duration (24 months, between 2009 - 2011)
The total FACT-Leu score consists of 44 items with total scores ranging from 0 to 176. Higher scores indicate better HRQoL. Negative changes from baseline indicate a worsening of HRQoL while positive changes indicate an improvement in HRQoL. A response of "Worsened" was a change from baseline in score of less than or equal to -11.
AstraZeneca
Industry
A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged ≥ 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML)
Acronym: SPARK-AML1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03836209
Acute Myeloid Leukemia, Hematologic Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT03374332
Acute Myeloid Leukemia, Disease Attributes
Providence, Rhode Island, United States
View Trial DetailsNCT03455504
Acute Myeloid Leukemia, Hematologic Diseases
Bergamo, Italy
View Trial DetailsNCT03480360
Acute Myeloid Leukemia, Anemia
Lebanon, New Hampshire, United States
View Trial Details